Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)	6 Months Ended
	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Number of Tumor Samples	150,000
Number of Reportable Segments	1
Retained Earnings (Accumulated Deficit)	$ (184,939,606)			$ (180,426,271)
Cash and Cash Equivalent	506,078			611,822
Liabilities, Current	3,845,439			3,593,401
Operating Lease, Liability, Noncurrent	1,243,327			1,558,239
Net Cash Provided by (Used in) Operating Activities, Continuing Operations	(4,280,632)	$ (5,504,158)
Equity, Attributable to Parent	$ (1,653,400)	$ 4,093,971	$ (145,796)	$ (202,610)	$ 1,966,969	$ 4,053,671	$ 8,271,780